Add to ORKGdeath from coronary heart disease in older patients with previous coronary heart disease and average cholesterol levels is uncertain. Objective: To compare the relative and absolute effects of prav-astatin on cardiovascular disease outcomes in patients with coro-nary heart disease who are 65 years of age or older with those in patients 31 to 64 years of age. Design: Subgroup analysis of a randomized, placebo-controlled trial
Context: Studies have demonstrated that statins administered to individuals with risk factors for co...
Item does not contain fulltextOBJECTIVES: To assess the effect of preventive pravastatin treatment o...
Background We compared cost-effectiveness of pravastatin in a placebo-controlled trial in 5500 young...
Background Although statins reduce coronary and cerebrovascular morbidity and mortality in middle-ag...
Background Although statins reduce coronary and cerebrovascular morbidity and mortality in middle-ag...
BACKGROUND: The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), a placebo-control...
Background: The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), a placebo-control...
Background Although statins reduce coronary and cerebrovascular morbidity and mortality in middle-ag...
Background Although statins reduce coronary and cerebrovascular morbidity and mortality in middle-ag...
The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), a placebo-controlled trial of...
The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), a placebo-controlled trial of...
OBJECTIVES: To assess the effect of preventive pravastatin treatment on coronary heart disease (CHD)...
<div><p>Background</p><p>The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), a pl...
OBJECTIVES: To assess the effect of preventive pravasta-tin treatment on coronary heart disease (CHD...
<br>Background: The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), a pl...
Context: Studies have demonstrated that statins administered to individuals with risk factors for co...
Item does not contain fulltextOBJECTIVES: To assess the effect of preventive pravastatin treatment o...
Background We compared cost-effectiveness of pravastatin in a placebo-controlled trial in 5500 young...
Background Although statins reduce coronary and cerebrovascular morbidity and mortality in middle-ag...
Background Although statins reduce coronary and cerebrovascular morbidity and mortality in middle-ag...
BACKGROUND: The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), a placebo-control...
Background: The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), a placebo-control...
Background Although statins reduce coronary and cerebrovascular morbidity and mortality in middle-ag...
Background Although statins reduce coronary and cerebrovascular morbidity and mortality in middle-ag...
The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), a placebo-controlled trial of...
The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), a placebo-controlled trial of...
OBJECTIVES: To assess the effect of preventive pravastatin treatment on coronary heart disease (CHD)...
<div><p>Background</p><p>The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), a pl...
OBJECTIVES: To assess the effect of preventive pravasta-tin treatment on coronary heart disease (CHD...
<br>Background: The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), a pl...
Context: Studies have demonstrated that statins administered to individuals with risk factors for co...
Item does not contain fulltextOBJECTIVES: To assess the effect of preventive pravastatin treatment o...
Background We compared cost-effectiveness of pravastatin in a placebo-controlled trial in 5500 young...